Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

EASL 2021: Rapid Recap by Dr. Tarik Asselah

June 23-26, 2021; Virtual
Hear a rapid update of the top HBV, HCV, and HDV studies from the Virtual 2021 International Liver Congress, 2021.
Tarik Asselah, MD, PhD
Released: July 20, 2021

Information on this Educational Activity

Faculty

Tarik Asselah, MD, PhD

Professor of Medicine
Department of Hepatology
Hôpital Beaujon
Université de Paris
Clichy, France

Tarik Asselah, MD, PhD, has disclosed that he has received consulting fees from AbbVie, Eiger, Gilead Sciences, Janssen, MYR Pharmaceuticals, and Roche.

Staff

Elaine P. Seeskin

Editorial Contributor

Elaine P. Seeskin has no relevant conflicts of interest to report.
Jennifer Blanchette, PhD

Senior Scientific Director

Jennifer M. Blanchette, PhD, has no relevant conflicts of interest to report.
Edward King, MA

Executive Vice President

Edward King, MA, has no relevant conflicts of interest to report.
Jenny Schulz, PhD

Director, Scientific Services

Jenny Schulz, PhD, has no relevant conflicts of interest to report.
Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.
Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.
Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP

Executive Vice President, Educational Strategy
General Manager, Oncology

Tina B Stacy, PharmD, has no relevant conflicts of interest to report.

Program Medium

This program has been made available online.

Related Content

Robert Gish on cure strategies at EASL 2021: si RNAs, JNJ-3989, AB-729, GSK3228836, VIR-3434, c-PAMs or capsid inhibitors, AB-836, and more from Clinical Care Options (CCO)

Robert G. Gish, MD Released: July 22, 2021

Top EASL 2021 studies from Clinical Care Options (CCO) and Stefan Zeuzem: HBV Cure, HCV point-of-care testing and treatment cascade, utility of SVR4, emerging HDV treatments

Stefan Zeuzem, MD Released: July 22, 2021

Commentary from Nancy Reau on HDV and HBV

Nancy Reau, MD Released: July 22, 2021

CCO slideset: key viral hepatitis studies EASL 2021, including treatment of HDV, HBV, HCV in in adults and children, linking patients to care, HBV cure, and more

Tarik Asselah, MD, PhD Robert G. Gish, MD Nancy Reau, MD Stefan Zeuzem, MD Released: July 15, 2021
Educational grant provided by:
AbbVie
Antios Therapeutics
Gilead Sciences, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue